Fly strains UAS-GFP (Bloomington Stock #6874), TH-Gal4 (Bloomington Stock #8848), CatalaseRNAi (Bloomington Stock #34020) and PHGPx (Bloomington Stock #33939), were obtained from Bloomington stock center, Indiana, along with park 13 (Bloomington Stock #79210) as the Parkinsonian disease model
Plasma exposure of PF-06882961, as measured by AUC inf and C max , appeared to increase in an approximately dose-proportional manner, with mean t 1/2 ranging from 4.3 to 6.1 hours (Fig
If youre looking for IV therapy in San Ramon or the Tri-Valley , I highly recommend MedLounge
launch expected April Coordinated global commercialization My takeaway 1 Obesity drugs = new pharma battleground This is now a head-to-head innovation race, not just market expansion 2 Small efficacy differences = huge market impact Even a few percentage points shift prescribing behavior + billions in revenue 3 Lifecycle management is critical Higher doses, new pens, expanded indications = defending blockbuster franchises 4 Broader implication Expect continued competition across: GLP-1 / incretin space Combination therapies Next-gen metabolic drugs #Pharma #Obesity #GLP1 #NovoNordisk #EliLilly #DrugDevelopment #HealthcareInnovation To view or add a comment, sign in Eli Lilly and Company's orforglipron target raised by Wolfe analyst amid strong market potential orforglipron Eli Lilly obesity Wolfe analyst has raised the price target for Eli Lilly from $1250 to $1325, citing strong long-term demand for its experimental oral obesity drug, orforglipron
found that GF mice exhibited higher BBB permeability in various brain regions compared to pathogen-free (PF) mice, which was linked to reduced occludin and claudin-5 expression
That one answer separates an exclusion which clinical documentation cannot overcome and which is generally not appealable on medical grounds from a medical-necessity denial, which is appealable and frequently reversed
